These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 1090708)

  • 1. Computerized EEG: predictor of outcome in schizophrenia.
    Itil TM; Marasa J; Saletu B; Davis S; Mucciardi AN
    J Nerv Ment Dis; 1975 Mar; 160(3):118-203. PubMed ID: 1090708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sulpiride versus haloperidol in schizophrenia: a double-blind comparative trial.
    Cassano GB; Castrogiovanni P; Conti L; Bonollo L
    Curr Ther Res Clin Exp; 1975 Feb; 17(2):189-201. PubMed ID: 234359
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparison of phenothiazine and nonphenothiazine neuroleptics according to psychopathology, side effects and computerized EEG.
    Itil TM; Patterson CD; Keskiner A; Holden JM
    Adv Biochem Psychopharmacol; 1974; 9(0):499-509. PubMed ID: 4599437
    [No Abstract]   [Full Text] [Related]  

  • 4. Penfluridol (R 16341). A long-acting oral neuroleptic, as maintenance therapy for schizophrenic and mentally retarded patients. A placebo-controlled double-blind trial.
    Zwanikken GJ
    Psychiatr Neurol Neurochir; 1973; 76(2):83-92. PubMed ID: 4573494
    [No Abstract]   [Full Text] [Related]  

  • 5. Computerized EEG profiles of haloperidol, chlorpromazine, clozapine and placebo in treatment resistant schizophrenia.
    Small JG; Milstein V; Small IF; Miller MJ; Kellams JJ; Corsaro CJ
    Clin Electroencephalogr; 1987 Jul; 18(3):124-35. PubMed ID: 3652464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psychopharmacological correlates of post-psychotic depression: a double-blind investigation of haloperidol vs thiothixene in outpatient schizophrenia.
    Abuzzahab FS; Zimmerman RL
    J Clin Psychiatry; 1982 Mar; 43(3):105-10. PubMed ID: 7037757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dysphoric response to neuroleptic treatment in schizophrenia and its prognostic significance.
    Singh MM
    Dis Nerv Syst; 1976 Apr; 37(4):191-6. PubMed ID: 767080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Haloperidol and thiothixene in the long-term treatment of chronic schizophrenic outpatients in an urban community: social and vocational adjustment.
    Engelhardt DM; Rudorfer L; Rosen B
    J Clin Psychiatry; 1978 Dec; 39(12):834-40. PubMed ID: 721787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High vs standard dosage fluphenazine HCL in acute schizophrenia.
    Donlon PT; Meadow A; Tupin JP; Wahba M
    J Clin Psychiatry; 1978 Nov; 39(11):800-4. PubMed ID: 363702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
    J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amoxapine as an antipsychotic: comparative study versus haloperidol.
    Chaudhry IB; Husain N; Khan S; Badshah S; Deakin B; Kapur S
    J Clin Psychopharmacol; 2007 Dec; 27(6):575-81. PubMed ID: 18004123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Drug-response differences of high and standard dosage of fluphenazine-decanoate in relation to schizophrenic symptoms (author's transl)].
    Lehmann E; Quadbeck H; Tegeler J; Fararuni M; Heinrich K
    Pharmakopsychiatr Neuropsychopharmakol; 1980 May; 13(3):117-29. PubMed ID: 7393998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment with bromperidol in schizophrenic patients].
    Ellerman LA
    Acta Psiquiatr Psicol Am Lat; 1989; 35(1-2):23-30. PubMed ID: 2634329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The P 300 potential in schizophrenia].
    Laurent A; Garcia-Larrea L; Dalery J; Terra JL; D'Amato T; Marie-Cardine M; Mauguière F
    Encephale; 1993; 19(3):221-7. PubMed ID: 8275907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial.
    Akhondzadeh S; Safarcherati A; Amini H
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):253-9. PubMed ID: 15694232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conditioning in the prediction of drug withdrawal effects in chronic schizophrenic patients.
    Ban TA; Ananth JV; Lehmann HE
    Act Nerv Super (Praha); 1974 Mar; 16(1):23-33. PubMed ID: 4156144
    [No Abstract]   [Full Text] [Related]  

  • 17. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
    Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
    Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response of negative symptoms of schizophrenia to neuroleptic treatment.
    Serban G; Siegel S; Gaffney M
    J Clin Psychiatry; 1992 Jul; 53(7):229-34. PubMed ID: 1639741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative double-blind trial of fluspirilene and fluphenazine decanoate in the treatment of chronic schizophrenia.
    Winter K; Fullerton AG; Hussain K; Tarlo L
    Br J Clin Pract; 1973 Oct; 27(10):377-80. PubMed ID: 4601614
    [No Abstract]   [Full Text] [Related]  

  • 20. Flupenthixol in chronic schizophrenic inpatients: a controlled comparison with haloperidol.
    Ehmann TS; Delva NJ; Beninger RJ
    J Clin Psychopharmacol; 1987 Jun; 7(3):173-5. PubMed ID: 3298328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.